No one is in any doubt that these are hard times for life sciences companies. 

Some commentators have even suggested that these are the hardest times.   The cause is obvious enough: the paucity of capital that has blighted the ‘real’ economy has been felt even harder in the cash-hungry world of technology companies that lack any kind of revenue stream to help weather the storm.

But to attribute all the woes of the biotech industry to the credit crunch would be too simplistic.  Even as access to capital increases, and investors’ appetite for risk returns towards the long-term average, the troubles for life sciences companies may ease slightly but they will not go away.More

RxCelerate Ltd is an outsourced drug development platform based near Cambridge, UK. We specialize in delivering an entire road map of drug development services from discovery and medicinal chemistry through to formal preclinical development and clinical up to Phase IIa. In the last five years, we have witnessed dramatic changes in the drug development …